Asetazolamid etkileşimleri

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Alogliptin ve metformin etiketi, Kutulu uyarı)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (Asetazolamid etiketi, Uyarılar)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (Asetazolamid etiketi, Uyarılar)

CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (Atenolol ve klortalidon etiketi, Kontrendikasyonlar)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (Benazepril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (Asetazolamid etiketi, Uyarılar)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (Asetazolamid etiketi, Uyarılar)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Dapagliflozin ve metformin etiketi, Kutulu uyarı)

KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS [see… (Diklorfenamid etiketi, Kontrendikasyonlar)

In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (Dofetilid etiketi, İlaç etkileşimleri)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin-containing products, including JALYN. (Dutasterid ve tamsulosin etiketi, Uyarılar ve önlemler)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Empagliflozin ve metformin etiketi, Kutulu uyarı)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Enalapril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors. (Fentermin ve topiramat etiketi, Uyarılar ve önlemler)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (Fosinopril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Gentamisin etiketi, Kutulu uyarı)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g. , acute congestive heart failure), excessive alcohol intake, hepatic… (Glibenklamid ve metformin etiketi, Kutulu uyarı)

• Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. (Glimepirid etiketi, Kontrendikasyonlar)

• Hypersensitivity to sulfonamide derivatives. ▪ Known hypersensitivity to glipizide or any of the product's ingredients ( 4 ). ▪ Hypersensitivity to sulfonamide derivatives ( 4 ). (Glipizid etiketi, Kontrendikasyonlar)

In patients with hypersensitivity to sulfonamide-derived drugs. (Hidroklorotiyazid etiketi, Kontrendikasyonlar)

Known hypersensitivity to indapamide or to other sulfonamide-derived drugs. (İndapamid etiketi, Kontrendikasyonlar)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (İrbesartan ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

CONTRAINDICATIONS Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs. (Kandesartan ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

Because of the hydrochlorothiazide components, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Kinapril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed. (Kloroprokain etiketi, Önlemler)

Hypersensitivity to this product or to other sulfonamide-derived drugs. (Klorotiyazid etiketi, Kontrendikasyonlar)

THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Linagliptin ve metformin etiketi, Kutulu uyarı)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Lisinopril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. (Mekamilamin etiketi, Kontrendikasyonlar)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic… (Metformin etiketi, Kutulu uyarı)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (Metoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomisin etiketi, Kutulu uyarı)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (Olmesartan, amlodipin ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (Asetazolamid etiketi, Uyarılar)

Use in patients with known history of an allergic reaction to sulfonamide derivatives. (Pioglitazon ve glimepirid etiketi, Kontrendikasyonlar)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Pioglitazon ve metformin etiketi, Kutulu uyarı)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure ), excessive alcohol intake, hepatic… (Saksagliptin ve metformin etiketi, Kutulu uyarı)

• In patients who have demonstrated allergic-type reactions to sulfonamides [ see Warnings and Precautions (5.7) ]. (Selekoksib etiketi, Kontrendikasyonlar)

Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. (Sidofovir etiketi, Kontrendikasyonlar)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (Sitagliptin ve metformin etiketi, Kutulu uyarı)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, Addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. (Spironolakton ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (Tamsulosin etiketi, Uyarılar ve önlemler)

Kidney stones: avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidosis, or in patients on a ketogenic diet ( 5.13 ) (Topiramat etiketi, Uyarılar ve önlemler)

Hypersensitivity Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication. (Triamteren ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (Valsartan ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

…Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (Adrenalin etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Aliskiren etiketi, Uyarılar ve önlemler)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

Use with caution in patients with a known hypersensitivity to sulfonamides ( 5.8 ) (Almotriptan etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (Amikasin etiketi, İlaç etkileşimleri)

Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (Amiodaron etiketi, Uyarılar ve önlemler)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Amlodipin ve benazepril etiketi, Uyarılar ve önlemler)

In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (Amlodipin ve olmesartan etiketi, Uyarılar ve önlemler)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (Amlodipin ve valsartan etiketi, Uyarılar ve önlemler)

Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine… (Artikain ve adrenalin etiketi, İlaç etkileşimleri)

Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (Asebutolol etiketi, Uyarılar)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (Azilsartan etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Benazepril etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (Bromokriptin etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Like other members of this class of diuretics, bumetanide probably shares this risk. (Bumetanid etiketi, Uyarılar)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent… (Bupivakain ve adrenalin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Use with caution in patients with a known sulfonamide allergy. (Darunavir etiketi, Uyarılar ve önlemler)

Monitor in patients with a known sulfonamide allergy. (Darunavir ve kobisistat etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide reduces urinary excretion of quinidine and may enhance its effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

The concomitant administration of thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of PROGLYCEM. (Diazoksit etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume depleted, and the elderly. (Diflunisal etiketi, Uyarılar)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (Digoksin etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak ve misoprostol etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (Asetazolamid etiketi, İlaç etkileşimleri)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (Asetazolamid etiketi, İlaç etkileşimleri)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Duloksetin etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalapril etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Etodolak etiketi, Uyarılar)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

Acetazolamide modifies phenytoin metabolism with increased serum levels of phenytoin. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fenoprofen etiketi, Uyarılar ve önlemler)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fentanil etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (Flukonazol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fluoksetin etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Flurbiprofen etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fluvoksamin etiketi, Uyarılar ve önlemler)

Acetazolamide may increase the effects of other folic acid antagonists. (Asetazolamid etiketi, İlaç etkileşimleri)

• Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

Fosamprenavir calcium should be used with caution in patients with a known sulfonamide allergy. (Fosamprenavir etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Fosinopril etiketi, Uyarılar)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS: Drug Interactions). (Hidrokodon ve ibuprofen etiketi, Uyarılar)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidromorfon etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (İbuprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (İndometazin etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (İrbesartan etiketi, Uyarılar ve önlemler)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Kandesartan etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (Kaptopril etiketi, Uyarılar)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (Ketokonazol etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Ketorolak etiketi, Uyarılar ve önlemler)

Acetazolamide reduces urinary excretion of quinidine and may enhance its effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Urinary Alkalizers (Acetazolamide, Sodium Bicarbonate) Urinary alkalinizing agents may increase plasma quinine concentrations. (Kinin etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Hypokalemia can result from diuretic therapy, diarrhea, and other causes. (Klozapin etiketi, Uyarılar ve önlemler)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Kodein etiketi, İlaç etkileşimleri)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Kolestiramin etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Levorfanol etiketi, İlaç etkileşimleri)

Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Levosalbutamol etiketi, İlaç etkileşimleri)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent… (Lidokain ve adrenalin etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Linezolid etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Lisinopril etiketi, Uyarılar ve önlemler)

Acetazolamide increases lithium excretion and the lithium may be decreased. (Asetazolamid etiketi, İlaç etkileşimleri)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (Losartan etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Losartan ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Mefenamik asit etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Meloksikam etiketi, Uyarılar ve önlemler)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (Mepivakain etiketi, İlaç etkileşimleri)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Metadon etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (Asetazolamid etiketi, İlaç etkileşimleri)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Anticoagulants Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; dosage adjustments may be necessary. (Metolazon etiketi, İlaç etkileşimleri)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (Metoprolol etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been salt- and volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Moeksipril etiketi, Uyarılar)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Morfin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Nabumeton etiketi, Uyarılar)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Nadolol etiketi, Uyarılar)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Nalbufin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Naproksen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (Nifedipin etiketi, İlaç etkileşimleri)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Oksaprozin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksimorfon etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oliseridin etiketi, İlaç etkileşimleri)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (Olmesartan etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Olmesartan ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation. (Asetazolamid etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Parasetamol ve kodein etiketi, İlaç etkileşimleri)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Paroksetin etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Pentazosin ve nalokson etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting [see Dosage and Administration (2.1) ] . (Perindopril etiketi, Uyarılar ve önlemler)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Petidin etiketi, İlaç etkileşimleri)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Pindolol etiketi, Uyarılar)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (Pirimetamin etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Piroksikam etiketi, Uyarılar ve önlemler)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

Addition of a diuretic or other antihypertensive agent to prazosin hydrochloride capsules has been shown to cause an additive hypotensive effect. (Prazosin etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

…procaine, ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration… (Prilokain ve adrenalin etiketi, İlaç etkileşimleri)

Caution is advised when beginning, discontinuing, or changing the dose of acetazolamide in patients receiving primidone. (Asetazolamid etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid etiketi, İlaç etkileşimleri)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (Probenesid ve kolşisin etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

Diuretics : Codeine may reduce the efficacy of diuretics. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (Ramipril etiketi, Uyarılar ve önlemler)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN… (Ropivakain etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (Sakubitril ve valsartan etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

• Diuretics: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Salsalat etiketi, Uyarılar)

Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Sefepim etiketi, İlaç etkileşimleri)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Seftazidim etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

…inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone… (Siklofosfamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Sotalol etiketi, Uyarılar ve önlemler)

…drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. (Spironolakton etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume-depleted, and the elderly. (Sulindak etiketi, Uyarılar)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

Drug Interactions In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. (Sülfametoksazol ve trimetoprim etiketi, İlaç etkileşimleri)

Concomitant use of agents associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) may increase the risk for hyperkalemia [see Adverse Reactions ( 6.1 )] . (Takrolimus etiketi, Uyarılar ve önlemler)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tapentadol etiketi, İlaç etkileşimleri)

Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (Telmisartan etiketi, Uyarılar ve önlemler)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (Telmisartan ve amlodipin etiketi, Uyarılar ve önlemler)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Telmisartan ve hidroklorotiyazid etiketi, Uyarılar ve önlemler)

Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Consideration should be taken in patients being treated with antidiabetic agents. (Asetazolamid etiketi, İlaç etkileşimleri)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (Tobramisin etiketi, İlaç etkileşimleri)

Use of tolmetin may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see PRECAUTIONS: Drug Interactions ). (Tolmetin etiketi, Uyarılar)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

Lithium Like other diuretics, torsemide reduces the renal clearance of lithium, inducing a high risk of lithium toxicity. (Torasemid etiketi, İlaç etkileşimleri)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol ve parasetamol etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been salt- or volume-depleted as a result of prolonged treatment with diuretics, dietary salt restriction, dialysis, diarrhea, or vomiting. (Trandolapril etiketi, Uyarılar)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5) ] . (Trazodon etiketi, Uyarılar ve önlemler)

The effects of the following drugs may be potentiated when given together with triamterene: antihypertensive medication, other diuretics, preanesthetic and anesthetic agents, skeletal muscle relaxants (non-depolarizing). (Triamteren etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

• Diuretics: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (Valsartan etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Venlafaksin etiketi, Uyarılar ve önlemler)

Control patients with milder ventricular dysfunction, if possible, with optimum doses of digitalis and/or diuretics before verapamil treatment is started [see Drug Interactions ( 7.5 )] . (Verapamil etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (Asetazolamid etiketi, İlaç etkileşimleri)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (Amoksisilin etiketi, İlaç etkileşimleri)

Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (Ampisilin etiketi, İlaç etkileşimleri)

In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, beta-blockers should be administered cautiously. (Betaksolol etiketi, Uyarılar)

Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (Dronedaron etiketi, Uyarılar ve önlemler)

In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

…clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (Finasterid etiketi, İlaç etkileşimleri)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (Flekainid etiketi, İlaç etkileşimleri)

There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. (Gümüş sülfadiazin etiketi, Uyarılar ve önlemler)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (İmatinib etiketi, Uyarılar ve önlemler)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). (Memantin etiketi, İlaç etkileşimleri)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (Memantin ve donepezil etiketi, İlaç etkileşimleri)

Acetazolamide may prevent the urinary antiseptic effect of methenamine. (Asetazolamid etiketi, İlaç etkileşimleri)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Metilen mavisi etiketi, Uyarılar ve önlemler)

Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Metilprednizolon etiketi, İlaç etkileşimleri)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (Penisilin G etiketi, İlaç etkileşimleri)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (Pentoksifilin etiketi, İlaç etkileşimleri)

Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (Piperasilin ve tazobaktam etiketi, Uyarılar ve önlemler)

Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizolon etiketi, İlaç etkileşimleri)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Sülfadiazin etiketi, İlaç etkileşimleri)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Terbinafin etiketi, İlaç etkileşimleri)

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Triamsinolon etiketi, İlaç etkileşimleri)

Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. (Bisoprolol etiketi, İlaç etkileşimleri)

ECG intervals (PR, QRS, and QT) were not affected by concurrent mexiletine and digoxin, diuretics, or propranolol. (Meksiletin etiketi, İlaç etkileşimleri)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)